Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its fourth quarter and full year 2025 financial results, highlighting progress in its NKX019 clinical trials for autoimmune diseases with dose escalation to 4 billion cells per dose. Initial clinical data presentations are planned for 2026, supported by a strong cash position of $295.1 million expected to fund operations throu…